Plain-English translation of NCT06730256 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CT0596, which uses your own immune cells that are genetically modified in a laboratory to recognize and fight cancer cells. The study will see how safe and effective this medication is, and how your body processes it over time. You would be one of about 24 patients receiving this treatment.
Multiple myeloma and plasma cell leukemia can become resistant to standard cancer drugs, leaving patients with few options. This medication represents a newer approach—teaching your immune system to attack cancer cells directly—and researchers want to see if it can help patients whose disease has stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the treatment through an infusion (injection into your bloodstream), and the study team would carefully monitor you for safety and how well the medication works. You'll have blood tests and other checkups to track your response and any side effects. The study requires you to attend regular visits and stay in touch with the research team for up to 15 years to understand the long-term effects of this medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China